研究表明,减重药物可能会降低患有糖尿病的成年人的癌症和死亡风险。 Study suggests weight-loss drugs may lower cancer and death risks in adults with diabetes.

对170,000名患者记录进行的一项研究表明,Wegovy、Ozempic和Zepbound等减重药物可能会降低肥胖致癌的风险,降低美国患有糖尿病的成年人的总体死亡率。 A study of 170,000 patient records suggests weight-loss drugs like Wegovy, Ozempic, and Zepbound may lower the risk of obesity-related cancers and overall death in U.S. adults with diabetes. 与服用与体重下降无关的不同糖尿病药物的人相比,服用GLP-1药物的人的癌症风险低7%,死于任何原因的风险低8%。 Compared to those taking different diabetes drugs not linked to weight loss, those on GLP-1 drugs had a 7% lower cancer risk and an 8% lower risk of death from any cause. 这项研究突出了一种可能的联系,值得进一步调查,尽管它不能证明直接因果关系。 The study highlights a potential connection worth further investigation, though it cannot prove direct causation.